Reported results
- Third-quarter net sales increased 14.5 percent on a reported basis to $13.013 billion.
- Third-quarter comparable sales growth was 7.0 percent.
- Third-quarter GAAP diluted EPS was $0.53.
- Third-quarter adjusted diluted EPS was $1.42, which excludes specified items.
- Third-quarter GAAP net earnings were $920 million.
- Third-quarter net earnings excluding specified items were $2,477 million.
Guidance
- Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent.
- Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.
- Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.
Notes
Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business, and transferred the Amulet device and related accessories from Structural Heart to Electrophysiology on January 1, 2026.
Price and volatility reaction
The stock moved -1.9% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -6.8 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 102.45 | 2026-10-20 |
| Close after release | 100.51 | 2026-10-21 |
| Realised move | -1.9% | close to close |
| 30d ATM IV change | -6.8 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-21 (8-K, Item 2.02). Read the original filing on sec.gov.
